Bluebird Ventures

About The Fund

Bluebird Ventures is an investment fund that was established by Jeff Bird, a seasoned life sciences investor with nearly two decades of experience, particularly noted for his time at Sutter Hill Ventures. Bluebird Ventures was formed in 2019 with a focus on creating and investing in life sciences companies that hold the potential to make significant impacts on the world. Their specializations lie within the Biotech and Pharmaceuticals sectors, aiming to push the boundaries of medical science through financial support and strategic guidance. The fund generally engages in Seed to Series A investment rounds, with an investment range starting at a minimum of $100,000, a maximum cap set at $5,000,000, and a sweet spot for investment at $1,500,000. Through a deep understanding of the complexities inherent in the life sciences domain, Bluebird Ventures positions themselves as not merely investors, but partners to the founders and entrepreneurs they support. They hold a firm belief that success in the challenging healthcare market stems from effective management and operational excellence, alongside their financial contribution. Jeff Bird brings to the table his vast experience, including his tenure at Gilead Sciences as Senior Vice President of Business Operations and numerous leadership roles, such as CEO of Verinata Health before it was acquired by Illumina. Bluebird Ventures looks to connect with entities that are addressing significant, valuable problems in life science and are driven by passion, intellect, grit, and commitment. The company maintains a portfolio and has been part of various significant events in the life sciences community as evidenced by its website announcements, such as Nutcracker's $60 million Series A financing, Illumina's acquisition of Grail for $8 billion, and Helix's receipt of $33 million in NIH funding for Covid-19 response.